(Total Views: 612)
Posted On: 08/05/2020 1:39:50 PM
Post# of 155269
i was hoping to get some opinions here. i have been looking into this the best that i could. In my humble opinion:
Regeneron's antibody cocktail p3 results in September are significant competition during CYDY's p3 interim result deadline. Are any of you concerned that the passive immunity may thwart the need for leronlimab? if we bind the virus with Regn-COV2 then less virus will bind ccr - laden macrophages/t cells thereby reducing Rantes levels indirectly. This does not even take in effect the passive immunity (if proven safe and effective) give prophylactically in reducing the number infected.
Does the world wide nature of the pandemic suggest that we will need multiple therapeutics anyway despite Regeneron's possible therapeutic offering?
Would appreciate any feedback.
Regeneron's antibody cocktail p3 results in September are significant competition during CYDY's p3 interim result deadline. Are any of you concerned that the passive immunity may thwart the need for leronlimab? if we bind the virus with Regn-COV2 then less virus will bind ccr - laden macrophages/t cells thereby reducing Rantes levels indirectly. This does not even take in effect the passive immunity (if proven safe and effective) give prophylactically in reducing the number infected.
Does the world wide nature of the pandemic suggest that we will need multiple therapeutics anyway despite Regeneron's possible therapeutic offering?
Would appreciate any feedback.
(1)
(0)
